Minocycline Hydrochloride | Medicis (Valeant) | ||
45,65,90,115,135 mg; Tablet ER |
Less Than $1000 mn
|
||
Less Than 5
|
More Than 5
|
||
Less Than 5
|
None | ||
More Than 5
|
More Than 5
|
||
None | |||
No
|
Solodyn | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 |
---|---|---|---|---|---|---|
***** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* |
**** (****) | ******* | ******* | ******* | ******* | ******* | ******* |
***** | ******* | ******* | ******* | ******* | ******* | ******* |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
***** | *** \ ** | *** ********* | *** ********* | ******** ************ | *** ** ****** |
**** (****) | ** \ ** | **** **, **** | ******* | ******** | ** **** ******** ** ***** **, **** |
***** | ** \ ** | **** **, **** | ******* | ******** | ******** ** **** **, **** |
Minocycline Hydrochloride | Medicis (Valeant) | ||
80mg, 105mg; Tablet ER |
Less Than $1000 mn
|
||
Less Than 5
|
More Than 5
|
||
Less Than 5
|
None | ||
More Than 5
|
Less Than 5
|
||
Indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. | |||
Yes
|
Solodyn | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 |
---|---|---|---|---|---|
*** (*******) | ******* | ******* | ******* | ******* | ******* |
********* | ******* | ******* | ******* | ******* | ******* |
***** | ******* | ******* | ******* | ******* | ******* |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
*** (*******) | *** \ ** | *** **, **** | ******* | ******** | *** ****** *** **** |
********* | ** \ ** | *** *, **** | ******* | ******** | ******** ** *** * |
***** | ** \ ** | *** **, **** | ******* | **** | ****** **** ******** |
Minocycline Hydrochloride | Medicis (Valeant) | ||
55mg; Tablet, Extended release |
Less Than $1000 mn
|
||
Less Than 5
|
More Than 5
|
||
None |
Less Than 5
|
||
Less Than 5
|
Less Than 5
|
||
Indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. | |||
Yes
|
Solodyn | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 |
---|---|---|---|---|---|---|
***** | ******* | ******* | *** ********* | *** ********* | ******* | *** ********* |
********* | ******* | ******* | *** ********* | *** ********* | *** ********* | *** ********* |
***** | ******* | ******* | *** ********* | *** ********* | *** ********* | *** ********* |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
***** | ** \ ** | ** | ******* | ******** | ******** ** *** **, **** |
********* | ** \ ** | *** **, **** | ******* | ******** | ******** ** *** **, **** |
***** | *** \ *** | *** **, **** | ******* | ******** | ******** ** *** **, **** |
Download ParaIV Report
Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
---|